Director, Worldwide Medical Oncology, Medical Communications at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Deep understanding of relevant disease states, medical education, scientific customer experience, and communication within WWMO
Experience managing across a global matrix organization
Strong business acumen with ability to interface with matrix partners, make trade-off decisions, and manage Medical Communications Asset/Indication-level budget and resource allocation
Ability to leverage digital, omnichannel tools, and AI-driven solutions to innovate Medical Communication strategies

Responsibilities

Collaborate effectively with alliance partners to drive joint initiatives, ensure alignment on strategic objectives, and facilitate seamless communication across cross-functional teams
Manage quality planning and timely communication of key scientific information for BMS assets within specified therapeutic areas
Serve as core member of the AIMS team to establish clear, viable, and compelling strategy for TA-specific Medical Communications, aligned with WWMO vision, strategy, and objectives
Ensure delivery of timely and high-quality medical publications, scientific content, medical education, and congress presentations worldwide
Chair the Medical Communications Working Group and deliver associated AIMS deliverables (3-year strategic/18-month tactical Medical Communications plan and Scientific Narrative & Platform)
Own development, pull-through, and execution of the Scientific Narrative aligned with portfolio strategy
Develop and execute functionally integrated publication plan, content plan, and application to the Scientific Communication Platform (SCP)
Lead development of personalized medical communications and ensure timely journal submissions, publications, Congress presentations, and delivery of internal/external scientific content
Drive strategy and execution of Pumitamig (BNT327/BMS986545) medical communication plans across multiple therapy areas (e.g., lung, breast, GI) to ensure pull-through of the Scientific Narrative
Create scientific communication strategic plans for specific disease areas, publication tactics, materials for scientific exchange, scientific narrative and platform, and external communication tools aligned with business needs in Medical Affairs and Clinical Development
Build and foster relationships across alliance partners and ensure alignment and pull-through of strategy across medical communication plans

Skills

Medical Communications

Oncology

Publication Planning

Scientific Narrative

Medical Affairs

Clinical Development

Disease State Expertise

Strategic Planning

Stakeholder Management

Thoracic Oncology

Head and Neck Cancer

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free